May 29, 2016 – – TheProductLawyers.com reports on Xarelto, approved in 2011 by the U.S. Food and Drug Administration (FDA). The drug’s purpose is to impede strokes and blood clots for people suffering from a number of medical conditions or recovering from specific surgical procedures such as hip and knee replacement surgeries. An additional use of the blood thinner was added later to treat a common heart condition called atrial fibrillation. Since the drug’s approval, it has become the subject of controversy. The FDA has given the drug two black box warnings which are the harshest warnings that a product can get before it is potentially removed completely from the consumer market.

Xarelto is manufactured by a subsidiary company of the Johnson and Johnson Corporation, Janssen Pharmaceuticals, as well as by Bayer AG. Since its release on the market, Xarelto, and its manufacturers have been the focus of thousands of lawsuits including 550 in Philadelphia, PA consolidated by the Court of Common Pleas, and over 2,800 others consolidated in a multidistrict litigation (MDL) in Eastern Louisiana assigned number 2592. In all of these cases up to this point, the plaintiffs have alleged that the drug causes sudden instances of uncontrollable bleeding. A new one, however, is notably different from the others in that it focuses on a new concern related to the marketed once-daily dosage regardless of the weight or size of the patient.

Xarelto is a once a day treatment, whereas, other blood thinners need to be taken twice daily. This new suit alleges that the once daily requirement is an ineffective amount. In this particular case, filed in October of 2015, the plaintiff suffered a stroke only 4 days after starting his treatment, as he was told he would be at risk of strokes due to his atrial fibrillation. He claims that not only did the drug not prevent his stroke he feels that Xarelto may have actually caused it.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60010276

May 29, 2016 – – LipsigLawyers.com reports on a news release from New York Daily News with updates regarding the owner of an e-cigarette shop in a Brooklyn mall kiosk where a young 14-year-old boy was allegedly blinded in his left eye when one of the e-cigarette devices there exploded in his hands. The story indicates that the owner of the shop “was previously convicted for his role in a ring selling illegal bath salts.”

With further details, the release states “ . . . the owner of Vape On in the Kings Plaza Mall in Mill Basin was one of 15 people arrested in 2011 for involvement in a Seattle-based ring that sold $2 million worth of the synthetic stimulant in shops in Manhattan and Brooklyn.”

Prior reports noted that the young boy had traveled to the mall with a group of friends on April 5, 2016, when they stopped to visit the Vape shop. It is alleged that a salesperson there began to show the group products, and had plugged an e-cigarette into the wrong battery when it suddenly exploded in the child’s hands, sending shards of metal into his eyes, and causing him to suffer chemical burns and scarring.

In the aftermath of this troubling incident, the boy and his father have chosen to pursue legal action. Their attorney, Marc Freund of Lipsig, Shapey, Manus & Moverman, noted that the kiosk was able to operate without insurance and to target minors without displaying any of the city-mandated signage. “This is shockingly reckless disregard for child safety by the mall,” Freund told the news outlet.

Attorney Freund is currently helping several clients pursue legal action following alleged e-cigarette explosion injuries, including a woman from New York who was reportedly parking her car when her e-cigarette device exploded, causing her to suffer painful burns to her leg, and launching the device into her dashboard. He has recommended that anyone who has suffered injuries following an e-cigarette explosion should take advantage of the opportunity to evaluate their legal options in the matter. Those affected may be entitled to significant compensation gained through legal action.

To request additional information on this topic, or to ask questions at any time, please contact Attorney Freund of Lipsig, Shapey, Manus & Moverman by calling 877-711-9545.

###

Contact LipsigLawyers.com:

Marc Freund
877-711-9545
mfreund@lipsig.com
40 Fulton St, New York, NY 10038

ReleaseID: 60010251

May 29, 2016 – – TheProductLawyers.com reports on the daily dosage requirements of Xarelto, as compared to other blood-thinning drugs, and a new lawsuit that disputes claims by the manufacturers of the drug that the recommended dosage is adequate for the medication to work. Most blood-thinning drugs that preceded Xarelto required the patient to take 2 pills a day in order to ensure the body was sufficiently medicated for a time period of 24 hours. Xarelto’s dosage is only one pill per day, unlike any other blood thinner currently on the market.

A new lawsuit, filed October 8, 2015, against Janssen Pharmaceuticals, a division of the Johnson and Johnson Corporation, and Bayer AG, directly calls into question the effectiveness of only taking Xarelto once a day. While many lawsuits up to this point focused on the increased risk of excessive bleeding caused by Xarelto, this is the first lawsuit that directly refutes the daily dosage requirement, and raise serious concerns over the “one-size-fits-all” mentality regardless of weight or size of the patient.

The plaintiff in this particular case claims in his court filing that the once daily dosage is ineffective, in that he states he suffered a stroke only four days after starting his treatment with Xarelto. He was purposely using Xarelto to prevent strokes, which he was deemed susceptible to having due to his atrial fibrillation. The plaintiff is claiming that not only did it not prevent his stroke, he believes that it may, in fact, have actually precipitated it.

Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011 to treat a number of conditions as well as patients recovering from some surgical procedures. Since the FDA’s approval, it has issued two black box warnings directly calling into question the future market availability of the drug. It has also been the subject of thousands of consolidated lawsuits in Philadelphia, PA (550 cases), as well as in Eastern Louisiana (in excess of 2,800 cases).

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60010275

May 29, 2016 – – LipsigLawyers.com reports on the details of a news release from Market Watch questioning the reasons behind recent reports of e-cigarette explosions. The article states that “A hospital in Seattle reports that e-cigarette injuries used to be a rare occurrence, but now the hospital is seeing at least one patient a month from e-cigarette related injuries.” As e-cigarette devices become increasingly popular, reports of them exploding increase as well. The general public has expressed mounting concerns over these devices and their overall safety.

E-cigarettes work by vaporizing nicotine-based liquids, often called “juice” by those who use the products. According to the release, statistics show that “One in four high-school students reported having used an e-cigarette in 2014, with one in eight saying they had smoked one in the last 30 days, according to the Centers for Disease Control and Prevention. E-cigarette sales were expected to hit $1.5 billion in 2015, according to Wells Fargo, with the market for vaporizing products–which includes e-cigarettes–reaching $10 billion by the end of 2018.”

Many have indicated that it is the lithium ion batteries of these devices that are actually exploding, and that these batteries are able to overheat. It was reported that the U.S. Fire Administration examined 25 media reports of these devices exploding between the years of 2009 and 2014, and determined that 80% of the incidents occurred while the e-cigarettes were charging.

Recently, a 17-year-old boy suffered painful burns when one of his classmate’s e-cigarette devices allegedly exploded in class. Another woman from New York reported driving when her e-cigarette battery exploded, burning her leg and launching the device into her dashboard.

Attorney Marc Freund of Lipsig, Shapey, Manus & Moverman is working to assist this woman as she pursues legal action in the aftermath. He is currently helping several clients to do so, and greatly encourages anyone who has been burned following an e-cigarette explosion to explore their legal rights fully. These individuals may be entitled to substantial compensation. To better assist affected parties, Attorney Freund is now offering free legal consultations.

To request additional information, or to ask questions, please contact Attorney Freund by calling 877-711-9545.

###

Contact LipsigLawyers.com:

Marc Freund
877-711-9545
mfreund@lipsig.com
40 Fulton St, New York, NY 10038

ReleaseID: 60010252

May 29, 2016 – – LipsigLawyers.com’s Thomas Moverman recently expressed satisfaction with the Occupational Safety and Health Administration’s move to require new methods of record keeping for construction employers.

The new rule, which will take effect August 10th, indicates that “construction industry employers with between 20 and 249 employees must send data from OSHA Form 300A to the agency electronically.” In addition, “ all industries with 250 or more employees must also include information from Forms 300 and 301,” according to an article by Construction Dive. Despite pushback from the construction industry claiming that publishing the data will expose private company information, agency officials noted that the new record-keeping rules are aimed at prompting construction companies to provide safer work environments for their employees.

The new requirements come just in time. According to the Bureau of Labor Statistics, 933 construction-related accidents in the U.S resulted in a fatality in 2014. That number steadily increased since 2011 when the total reached 781 fatalities. In non-fatal incidents, common injuries have included fractured or broken bones, spinal injuries and brain injuries. There are several different ways construction workers can be injured on the job. Among the most frequent are slips, trips and falls, scaffolding accidents, and falls from ladders.

Lipsig, Shapey, Manus & Moverman believes that victims of construction accidents are entitled to the representation and compensation they deserve. The firm has been representing victims of construction accidents for a combined 80 years and, in that time, has helped win over $500 million in settlements. Attorney Moverman has even represented one victim who was awarded $2.6 million after injuring his knee and back in a fall from defective scaffolding. The firm is currently offering free consultations to parties who have been injured in a construction accident. Qualifying individuals may be entitled substantial financial compensation.

For more information on construction injuries, or to schedule a consultation, call (646) 846-4496.

###

Contact LipsigLawyers.com:

Marc Freund
877-711-9545
mfreund@lipsig.com
40 Fulton St, New York, NY 10038

ReleaseID: 60010266

May 29, 2016 – – TheProductLawyers.com reports on a lawsuit filed by an Ohio couple requesting over $150,000 to compensate them for pain and suffering related to the alleged adverse side effects of taking Xarelto, a blood-thinning drug approved by the U.S. Food and Drug Administration in 2011. The wife of the plaintiff couple was given Xarelto to treat her atrial fibrillation. After taking Xarelto for two months, she very suddenly experienced a gastrointestinal bleed, and anemia, as well as other injuries not specifically identified. The woman claims to still be impacted by the side effects of the drug that require long-term maintenance and monitoring. The monetary payment being sought is to cover both current and future medical bills related to her condition.

This lawsuit, along with over 3,400 others all across the country, has been brought against the makers of the drug, Janssen Pharmaceuticals, a division of corporate giant Johnson and Johnson, and Bayer AG. The plaintiffs in this case, as well as the others, commonly allege that the use of the anticoagulant has made the risk of experiencing instances of excessive bleeding more likely. Some of the bleeding episodes have proven to be fatal. The plaintiffs also generally claim that the manufacturers of Xarelto failed to adequately and sufficiently inform the public and those medical professionals prescribing the drug of the dangers and risks involved in using it.

When Xarelto was initially approved by the FDA its intended use was for treating patients with medical conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. The drug was also designed to treat patients that had undergone hip and knee replacement surgeries. The FDA has now issued two black box warnings for the blood thinning drug. Black box warnings are considered quite severe and a telling indication that a product could be on the verge of being wholly removed from the consumer market.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60010274